Article | Published:

Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification

Nature Biotechnology volume 32, pages 577582 (2014) | Download Citation

Abstract

Genome editing by Cas9, which cleaves double-stranded DNA at a sequence programmed by a short single-guide RNA (sgRNA), can result in off-target DNA modification that may be detrimental in some applications. To improve DNA cleavage specificity, we generated fusions of catalytically inactive Cas9 and FokI nuclease (fCas9). DNA cleavage by fCas9 requires association of two fCas9 monomers that simultaneously bind target sites 15 or 25 base pairs apart. In human cells, fCas9 modified target DNA sites with >140-fold higher specificity than wild-type Cas9 and with an efficiency similar to that of paired Cas9 'nickases', recently engineered variants that cleave only one DNA strand per monomer. The specificity of fCas9 was at least fourfold higher than that of paired nickases at loci with highly similar off-target sites. Target sites that conform to the substrate requirements of fCas9 occur on average every 34 bp in the human genome, suggesting the versatility of this approach for highly specific genome-wide editing.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Accessions

Primary accessions

Sequence Read Archive

References

  1. 1.

    et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 343, 84–87 (2014).

  2. 2.

    et al. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 26, 808–816 (2008).

  3. 3.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

  4. 4.

    , , , & Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279–284 (2014).

  5. 5.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

  6. 6.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

  7. 7.

    et al. RNA-programmed genome editing in human cells. eLife 2, e00471 (2013).

  8. 8.

    et al. High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity. Nat. Biotechnol. 31, 839–843 (2013).

  9. 9.

    et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013).

  10. 10.

    et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013).

  11. 11.

    , , & CRISPR/Cas9 systems targeting β-globin and CCR5 genes have substantial off-target activity. Nucleic Acids Res. 41, 9584–9592 (2013).

  12. 12.

    et al. Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. Genome Res. 24, 132–141 (2014).

  13. 13.

    et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833–838 (2013).

  14. 14.

    et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).

  15. 15.

    , , & Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc. Natl. Acad. Sci. USA 109, E2579–E2586 (2012).

  16. 16.

    et al. Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res. 40, 5560–5568 (2012).

  17. 17.

    et al. Targeted gene addition to a predetermined site in the human genome using a ZFN-based nicking enzyme. Genome Res. 22, 1316–1326 (2012).

  18. 18.

    , & FokI requires two specific DNA sites for cleavage. J. Mol. Biol. 309, 69–78 (2001).

  19. 19.

    , , & Revealing off-target cleavage specificities of zinc-finger nucleases by in vitro selection. Nat. Methods 8, 765–770 (2011).

  20. 20.

    et al. Broad specificity profiling of TALENs results in engineered nucleases with improved DNA-cleavage specificity. Nat. Methods 11, 429–435 (2014).

  21. 21.

    et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014).

  22. 22.

    et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 31, 6176 (2014).

  23. 23.

    et al. A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat. Biotechnol. 27, 1186–1190 (2009).

  24. 24.

    et al. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152, 1173–1183 (2013).

  25. 25.

    et al. Orthogonal Cas9 proteins for RNA-guided gene regulation and editing. Nat. Methods 10, 1116–1121 (2013).

  26. 26.

    , & TALENs and ZFNs are associated with different mutation signatures. Nat. Methods 10, 185–185 (2013).

  27. 27.

    et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat. Biotechnol. (20 April 2014).

  28. 28.

    et al. Enhancing zinc-finger-nuclease activity with improved obligate heterodimeric architectures. Nat. Methods 8, 74–79 (2011).

  29. 29.

    & Near-infrared fluorescent proteins for multicolor in vivo imaging. Nat. Methods 10, 751–754 (2013).

  30. 30.

    , & NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671–675 (2012).

  31. 31.

    et al. in Engineering Zinc Finger Proteins (eds. Mackay, J.P. & Segal, D.J.) 247–256 (Humana Press, 2010).

  32. 32.

    et al. In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites. Nucleic Acids Res. 41, e181 (2013).

Download references

Acknowledgements

J.P.G., D.B.T. and D.R.L. were supported by Defense Advanced Research Projects Agency HR0011-11-2-0003 and N66001-12-C-4207, US National Institutes of Health NIGMS R01 GM095501 (D.R.L.) and the Howard Hughes Medical Institute (HHMI). D.R.L. was supported as a HHMI Investigator. We thank R. McDonald for technical assistance and V. Pattanayak for helpful comments.

Author information

Author notes

    • John P Guilinger
    •  & David B Thompson

    These authors contributed equally to this work.

Affiliations

  1. Department of Chemistry & Chemical Biology, Harvard University, Cambridge, Massachusetts, USA.

    • John P Guilinger
    • , David B Thompson
    •  & David R Liu
  2. Howard Hughes Medical Institute, Harvard University, Cambridge, Massachusetts, USA.

    • John P Guilinger
    • , David B Thompson
    •  & David R Liu

Authors

  1. Search for John P Guilinger in:

  2. Search for David B Thompson in:

  3. Search for David R Liu in:

Contributions

J.P.G. and D.B.T. performed the experiments, designed the research, analyzed the data and wrote the manuscript. D.R.L. designed the research, analyzed the data and wrote the manuscript.

Competing interests

The co-authors have filed a provisional patent application related to this work. D.R.L. is a consultant for Editas Medicine, a company that applies genome editing technologies for human therapeutic applications.

Corresponding author

Correspondence to David R Liu.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Figures 1–11, Supplementary Results, Supplementary Notes and Supplementary Tables 1–5

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt.2909

Further reading